Search results for: Norway
Filter search results
Measuring Value with Pharmacoeconomics
26 May 2011
…provinces in Canada. Since then, the UK has established NICE (1999) and several other European countries request economic analyses for at least some new medicines, including Belgium, Finland, Ireland, Norway,…
Is It Time to Reconsider the Role of Co-Payments in Europe?
11 January 2012
…Portugal, Slovakia, Slovenia and Spain 4. Uniform % Cyprus, Germany, Norway 5. Co-insurance, with % decreasing with accumulated expenditure over a given period and with a ceiling Denmark and Sweden…
Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe
28 November 2018
…(Netherlands, Norway and Poland), a single price ‘weighted’ by the value of each indication (Germany, France, Belgium and Austria) or individual prices for each indication (Italy). De facto, only the…
Rare Disease Day 2022
28 February 2022
…and Norway (all below 30%). OHE has also carried out research into the role of pharmaceutical innovation in the development of orphan medicines. In collaboration with EFPIA, we developed case…
NICE’s severity modifier: a step in the right direction, but still a long way to go
23 March 2022
…modifier). Furthermore, in Norway, AS is used to define severity, and the highest severity category is for undiscounted AS scores that exceed 20 (compared to discounted AS scores of ≥18)….
Achieving World Class Outcomes in Cancer Treatment
1 July 2011
…new international benchmarking programme, involving countries with reliable data — Denmark, Sweden, Norway, Canada and Australia – is intended in part to help determine why cancer survival rates differ. A…
Activity Based Funding for Hospitals: English Policy, International Experience
1 October 2004
…effects of different design specifications of the financial system. Egil Kjerstad, in Chapter 4, provides evidence from Norway showing the extent to which case payments can stimulate higher levels of…
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
…costs, including Belgium1, the Netherlands2, and Poland3. FIGURE 1: DISCOUNT RATES IN NATIONAL GUIDELINES FOR HEALTH ECONOMIC EVALUATIONS Sources: Canada4, France5, Belgium1, Germany6, Italy7, Singapore8, Denmark9, England10, Netherlands2, Norway11, Portugal12,…
Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
17 January 2024
…example, in Norway, the Norwegian Hospital Procurement Trust (Sykehusinnkjøp HF) introduced criteria to reduce the environmental impact of pharmaceutical products in 2019, and from 2020 to 2022, they launched eight…